摘要
Economic analysis of chronic diseases is required for proper allocation of resources and understanding costeffectiveness studies of new therapies. Studies on health care cost of ulcerative colitis （UC） and Crohn＇s disease （CD） are reviewed here. These studies were carried out in various countries with disparate health care systems. In the United States, data were often modeled or retrieved from large insurance schemes. Surgery and in-patient hospitalization accounted for over half the outlay on UC and CD. Fistulous disease in CD and parenteral nutrition were very costly. In Canada, overall charges were lower than in the United States, but there too, surgical costs were relatively high. In European studies, economic data were abstracted directly from patients＇ files. One pan-European study examined the outlay on UC and CD in a community-based prospective inception cohort followed for 10 years. Overall costs in Europe were lower than in the United States. Surgery, hospitalization, year of follow-up, disease phenotype in CD and ASCA-positivity impacted significantly on costs. In all studies, the cost data were right skewed, aminosalicylates were expensive drugs, and biological agents the most expensive; moreover indirect costs were not calculated. Infliximab raised costs considerably in CD, but there were no long-term followup studies, so that the cost-benefit of biological agents remains unknown. In conclusion, costs of managing UC and CD vary by country, surgery, genotype and several other factors. The most important question for further research is whether the biological therapies are cost-effective in the long-term.
慢性病的经济分析为资源的合适的分配和新治疗的理解划算研究被要求。护理上的研究 ulcerative (UC ) 花费了， Crohn 的疾病(CD ) 这里被考察。这些研究与迥异的护理系统在各种各样的国家被执行。在美国，数据经常从大保险计划被建模或检索。外科和住院病人住院说明了在 UC 和 CD 上的半 outlay 上。在 CD 和非肠道的营养的瘘的疾病是很昂贵的。在加拿大，全面费用比低在美国，但是在那里也，外科的费用相对高。在欧洲研究，经济数据从病人的文件直接被提炼。一泛欧的研究在跟随 10 年的一个基于社区的未来的开始队在 UC 和 CD 上检验了 outlay。在欧洲的全面费用比在美国低。外科，住院，后续的年，在 CD 和 ASCA 确实的疾病显型显著地影响了费用。在所有研究，费用数据恰好被扭曲的、氨基的水杨酸盐是昂贵的药，和生物代理人最昂贵；而且间接费用是不计算的。Infliximab 在 CD 更加提起了费用，但是没有长期的后续研究，以便未知的生物代理人遗体本利。在结论，管理 UC 和 CD 的费用由土地，外科，遗传型和几个另外的因素变化。为进一步的研究的最重要的问题是生物制品疗法是否是划算的在长期。
